Organization
Celgene International Sàrl
3 abstracts
Abstract
Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)‑naive transfusion-dependent (TD) patients (pts) with lower‑risk myelodysplastic syndromes (LR-MDS).Org: University of Texas M.D. Anderson Cancer Center, Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, University of Florence, AOUC, Yale School of Medicine and Yale Cancer Center, Yale University, Monash University and Monash Health,
Abstract
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.Org: Yale School of Medicine, Yale Cancer Center, Yale University, University Hospital Leipzig, Cancer Center IRCCS Humanitas Research Hospital,
Abstract
Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT).Org: MD Anderson Cancer Center, Bristol Myers Squibb, Evidera, Inc, Seràgnoli Institute of Hematology, Winship Cancer Center of Emory University,